ADC drug developer Trior raises $25M in Series C funding from Korea Development Bank, DS Asset Management, and others to advance platform technologies and drug pipelines.
Amount Raised
$25 Million
Round Type
Series C
Investors
Description
Trior, an antibody-drug conjugate therapeutics developer, closed a $25 million Series C round conducted as a multi-closing with two tranches. The first close brought $18 million from new investors including Korea Development Bank, DS Asset Management, HB Investment, SAGE ONE PARTNERS, and TESS Investment Partners. The second close added $6.8 million from existing investors including Woori Venture Partners, LSK Investment, Shinhan Capital, and Sneak Peek Investments. Trior plans to use the funds to advance its TROCAD and TROSIG platform technologies and accelerate development of its antibody therapeutic and ADC drug pipelines.
Quick answer
Trior raised $25 Million in a Series C round, dated October 23, 2026. Investors: Sneak Peek Investments, Shinhan Capital, LSK Investment, Woori Venture Partners, Honeypot Ventures, TESS Investment Partners, Sage One Partners and HB Investment.
- How much did Trior raise?
- Trior raised $25 Million in a Series C round on October 23, 2026.
- Who invested in Trior?
- Sneak Peek Investments, Shinhan Capital, LSK Investment, Woori Venture Partners, Honeypot Ventures, TESS Investment Partners, Sage One Partners and HB Investment are named as investors in this round.
- What does Trior do?
- Trior is a developer of antibody-drug conjugate (ADC) therapeutics with two proprietary platforms: TROCAD, a dual-function masking platform for improving therapeutic index of antibody-based therapies, and TROSIG, a..
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Trior that raised within 45 days of this round, from Fundz verified event records.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Biograil raised $22M on November 4, 2026.
- Quanta Therapeutics raised an undisclosed amount (Series D) on October 24, 2026.
- Pathos AI raised $237M (Series E) on October 23, 2026.
- Disc raised $422M (Post-IPO Equity) on October 20, 2026.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
Who to call at Trior, and when
A new round usually means Trior is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Trior raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Trior, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Trior. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Trior raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Trior raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.